Stocks
ResMed Financial Statements (RMD) |
||||||||||
| ResMedsmart-lab.ru | % | 2022 | 2023 | 2023 | 2024 | 2024 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.08.2022 | 30.06.2023 | 11.08.2023 | 30.06.2024 | 09.08.2024 | 25.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3 578 | 4 223 | 4 223 | 4 685 | 4 685 | 4 868 | |||
| Operating Income, bln rub | 1 000 | 1 132 | 1 132 | 1 398 | 1 320 | 1 528 | ||||
| EBITDA, bln rub | ? | 1 177 | 1 340 | 1 359 | 1 693 | 1 600 | 1 751 | |||
| Net profit, bln rub | ? | 779.4 | 897.6 | 897.6 | 1 021 | 1 021 | 1 196 | |||
| OCF, bln rub | ? | 351.1 | 693.3 | 693.3 | 1 401 | 1 401 | 1 608 | |||
| CAPEX, bln rub | ? | 156.0 | 134.0 | 134.0 | 114.9 | 114.9 | 95.4 | |||
| FCF, bln rub | ? | 195.1 | 559.3 | 559.3 | 1 286 | 1 286 | 1 512 | |||
| Dividend payout, bln rub | 245.3 | 258.3 | 258.3 | 282.3 | 282.3 | 289.5 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 31.5% | 28.8% | 28.8% | 27.7% | 27.7% | 24.2% | ||||
| OPEX, bln rub | 1 024 | 1 204 | 1 204 | 1 225 | 1 368 | 1 283 | ||||
| Cost of production, bln rub | 1 554 | 1 867 | 1 867 | 2 063 | 2 077 | 2 057 | ||||
| R&D, bln rub | 253.6 | 287.6 | 287.6 | 307.5 | 307.5 | 318.3 | ||||
| Interest expenses, bln rub | 22.3 | 47.4 | 47.4 | 45.7 | 45.7 | 29.8 | ||||
| Assets, bln rub | 5 096 | 6 752 | 6 752 | 6 872 | 6 872 | 7 222 | ||||
| Net Assets, bln rub | ? | 3 361 | 4 130 | 4 130 | 4 864 | 4 864 | 5 195 | |||
| Debt, bln rub | 917.6 | 1 580 | 1 580 | 873.9 | 873.9 | 850.2 | ||||
| Cash, bln rub | 273.7 | 227.9 | 227.9 | 238.4 | 238.4 | 426.4 | ||||
| Net debt, bln rub | 643.8 | 1 352 | 1 352 | 635.6 | 635.6 | 423.9 | ||||
| Ordinary share price, rub | 209.6 | 218.5 | 218.5 | 191.4 | 191.4 | 150.1 | ||||
| Number of ordinary shares, mln | 146.1 | 0.000 | 146.8 | 147.0 | 147.0 | 146.9 | ||||
| Market cap, bln rub | 30 620 | 0 | 32 068 | 28 143 | 28 143 | 22 047 | ||||
| EV, bln rub | ? | 31 264 | 1 352 | 33 420 | 28 778 | 28 778 | 22 471 | |||
| Book value, bln rub | 1 078 | 4 130 | 807 | 4 864 | 1 536 | 1 830 | ||||
| EPS, rub | ? | 5.34 | 6.12 | 6.94 | 6.94 | 8.15 | ||||
| FCF/share, rub | 1.34 | 3.81 | 8.75 | 8.75 | 10.3 | |||||
| BV/share, rub | 7.38 | 5.50 | 33.1 | 10.4 | 12.5 | |||||
| EBITDA margin, % | ? | 32.9% | 31.7% | 32.2% | 36.1% | 34.2% | 36.0% | |||
| Net margin, % | ? | 21.8% | 21.3% | 21.3% | 21.8% | 21.8% | 24.6% | |||
| FCF yield, % | ? | 0.64% | 0.00% | 1.74% | 4.57% | 4.57% | 6.86% | |||
| ROE, % | ? | 23.2% | 21.7% | 21.7% | 21.0% | 21.0% | 23.0% | |||
| ROA, % | ? | 15.3% | 13.3% | 13.3% | 14.9% | 14.9% | 16.6% | |||
| P/E | ? | 39.3 | 0.00 | 35.7 | 27.6 | 27.6 | 18.4 | |||
| P/FCF | 156.9 | 0.00 | 57.3 | 21.9 | 21.9 | 14.6 | ||||
| P/S | ? | 8.56 | 0.00 | 7.59 | 6.01 | 6.01 | 4.53 | |||
| P/BV | ? | 28.4 | 0.00 | 39.7 | 5.79 | 18.3 | 12.0 | |||
| EV/EBITDA | ? | 26.6 | 1.01 | 24.6 | 17.0 | 18.0 | 12.8 | |||
| Debt/EBITDA | 0.55 | 1.01 | 1.00 | 0.38 | 0.40 | 0.24 | ||||
| R&D/CAPEX, % | 162.5% | 214.7% | 214.7% | 267.7% | 267.7% | 333.8% | ||||
| CAPEX/Revenue, % | 4.36% | 3.17% | 3.17% | 2.45% | 2.45% | 1.96% | ||||
| ResMed shareholders | ||||||||||
